Drug discovery is a step-by-step process very important in biopharmaceutical field. We are interested in identifying new investigational drug-likes as potential inhibitors of determinate biological-therapeutic targets, trying to decrease the side effects and to safeguard the human health. However, it is a long and very expensive process. Therefore, we are using a new computational strategy, based on Pharmacophore modeling, to select bioactive substances (natural or synthetic), through the integration of bioinformatics online tools and local resource and platforms, in order to include into the strategy also knowledge from high-throughput studies, for new potential lead compounds generation-optimization, trying to accelerate the early phase of the drug development process. The protocol of this new computational strategy is characterized by a multi-step design focused on: 1) screening in RCSB-PDB for a crystal structure of a specific biological target, suitable for the following steps; 2) pharmacophore modeling and virtual computational screening, by using public domain databases of bioactive compounds, as the ZINC12 database [5], in order to find a promising molecule that could become a new potential medicine. 3) molecular and biological evaluation, to check the compounds selected by virtual screening, for their biological properties through public databases, as PubChem Compound, SciFinder, and Chemicalize to trace their origin and underline their most important physical-chemical features, PathPred (an enzyme-catalyzed metabolic pathway predictor server) to highlight and identify their biosynthetic-metabolic pathways and investigating the biotransformation of best candidates, analyzing their metabolites and their potential biological activity. Moreover, ADMET/toxicity predictor server applying the Lipinski-Veber filter are used to calculate the bioavailability the ADMET/toxicity properties. After this check, only molecules with good bioavailability, good predicted activity and good ADMET properties are considered as hits compounds or drug-likes to direct the design of next experimental assays [6]. Finally, the lead compounds selected are analyzed through molecular dynamics simulations. 4) simulations of molecular dynamics on the best lead compounds, to investigate atomic details of protein-compound molecular interactions in different conditions (different organic solutions, organisms and systems).
REFERENCES
[1] Dubey A, Facchiano A, Ramteke PW, Marabotti A. “In silico approach to find chymase inhibitors among biogenic compounds.” Future Med Chem. 2016; 8(8):841-51
[2] Dubey A, Marabotti A, Ramteke PW, Facchiano A. "Interaction of human chymase with ginkgolides, terpene trilactones of Ginkgo biloba investigated by molecular docking simulations.” Biochem Biophys Res Commun. 2016; 473(2):449-54.
[3] Katara P. “Role of bioinformatics and pharmacogenomics in drug discovery and development process”. Netw Model Anal Health Inform Bioinforma 2013; 2: 225-230.
[4] Sunseri J. and Koes D. R. “Pharmit: Interactive Exploration of Chemical Space”.Nucl. Acids Res. 2016; 44(W1): W442-448.
[5] Irwin J.J. and Shoichet B.K. “ZINC- A free database of Commercially Available Compounds for Virtual Screening”. J.Chem.Inf.Model. 2005; 45: 177-182.
[6] Kaserer T., Beck K. R., Akram M., Odermatt A., Schuster D. “Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Application Exemplified on Hydroxysteroid Dehydrogenases”.Molecules 2015; 20: 22799–22832.
Biological Evaluation of Endophytic Fungus Chaetomium sp. NF15 of Justicia adhatoda L.: A Potential Candidate for Drug Discovery
